An article written by Geno Germano, Group President, Global Innovative Pharma Business, Pfizer
How Pfizer Is Using Big Data To Power Patient Care, Forbes, 2/17/2015 @ 10:18AM
http://www.forbes.com/sites/matthewherper/2015/02/17/how-pfizer-is-using-big-data-to-power-patient-care/
In the current issue of Health Affairs :
February 2015; Volume 34, Issue 2 Biomedical Innovation
http://content.healthaffairs.org/content/34/2.toc
Outterson, K., J. H. Powers, G. W. Daniel and M. B. McClellan (2015). “Repairing The Broken Market For Antibiotic Innovation.” Health Affairs 34(2): 277-285. http://content.healthaffairs.org/content/34/2/277.abstract
“…Good public health practices curb inappropriate antibiotic use, making return on investment challenging in payment systems based on sales volume. We […]
Maruthappu, M. and B. Keogh (2014). How might 3D printing affect clinical practice? BMJ 2014;349:g7709 http://www.bmj.com/content/349/bmj.g7709
Changing clinical practice and business models:
“When added to the ever increasing availability of printers,… The internet is no longer simply an information vehicle but a delivery vehicle, decentralising and accelerating the manufacturing process.”
“…combined with medical imaging, 3D printing also has the potential to revolutionise […]
Diverging standards still enable profit production and local forms of value creation.
Achim Rosemann, Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine, Social Science & Medicine, Volume 122, December 2014, Pages 72-80,
http://www.sciencedirect.com/science/article/pii/S0277953614006649
Patients are changing, Governments are moving… “Pharmaceutical and medical-device companies have been slow to adopt digitization. Here are five reasons they should get moving…”
for digitally enabled healthcare…
The report is here: http://www.mckinsey.com/insights/health_systems_and_services/a_digital_prescription_for_pharma_companies
The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development
by Javier Lezaun and Catherine M. Montgomery
Science, Technology & Human Values January 2015 40: 3-29,
first published on July 11, 2014
doi:10.1177/0162243914542349
In the last decade, the organization of pharmaceutical research on neglected tropical diseases has undergone transformative change. In a context of perceived “market failure,” the development of […]
PatientsLikeMe, the largest online network for patients, has established its first broad partnership with a drug company. Genentech
http://www.technologyreview.com/
A blog post by Dom Marchant & Matt Lowe, on how “digital is no longer a bolt-on, but the predominant channel within pharma”, and ten things not to do in the business..
Read more at: http://www.pharmatimes.com/magazine/blogdetails.aspx?id=0ebffbc3-bed0-4c9b-b260-642dfec06c85#.Uwtko8umGU8.email#ixzz3L8Czz4sC
An article from Pharma Times, by Claire Bowie, on intellectual property and Pharma-University collaboration
Creating a new ecosystem for drug discovery
Pharma Times FEBRUARY 24, 2014